UNSPSC 85818920: Transfusion of nonautologous cord blood stem cells into central vein, percutaneous approach

This classification denotes the group of activities that yields a surgical intervention or procedure to transfusion of nonautologous cord blood stem cells into central vein, percutaneous approach. This surgical intervention or procedure is listed in the World Health Organization's International Statistical Classification of Diseases and Related Health Problems or ICD-10 as code 30243X1

UNSPSC 85818920, Transfusion of nonautologous cord blood stem cells into central vein, percutaneous approach, is a Commodity code that shows minimal recent alignment with actual state and local procurement activity. The recent opportunities tagged under this code do not involve cord blood stem cell transfusions or the specialized cellular therapy it nominally describes. Instead, the opportunities span occupational medical surveillance, pharmacy benefit management, temporary health professional staffing, disability medical evaluations, surgical benefit carve-out programs, and emergency medical services for youth in detention—none of which fall within the scope of the code's stated clinical procedure.

The mismatch between the UNSPSC code's taxonomy definition and the actual procurements posted under it suggests either systematic mis-tagging in state and local databases or that the code is being used as a catchall for health-related services outside its intended scope. The issuing bodies include the City of Phoenix Retirement Office (Arizona), the Washington State Department of Transportation on behalf of the Washington State Ferries (Washington), the City of Long Beach (California), Harris County Juvenile Probation Department (Texas), Collier County Board of County Commissioners (Florida), and the County of Santa Clara Health System (California). Recent opportunities are concentrated in Arizona, California, Florida, Texas, and Washington, with no recurring buyers using this code for the cellular therapy procedure it nominally describes. Given the absence of relevant cord blood stem cell procurement activity in the recent record, this code does not currently merit active pursuit for firms specializing in that treatment modality or related cell-therapy services.